Association Between Irbesartan and Erectile Dysfunction: A Comprehensive Analysis Incorporating Real-World Pharmacovigilance and Mendelian Randomization.

Background: Irbesartan is widely used for hypertension management, but its relationship with erectile dysfunction (ED) is unclear. This study combines real-world data from the FAERS database with Mendelian randomization to explore this potential association. Methods: We conducted multiple pharmacovi...

Descripción completa

Detalles Bibliográficos
Publicado en:Hospital Pharmacy Vol. 61; no. 1; pp. 59 - 68
Autores principales: Chen, Kaiqin, Cheng, Rui, Guo, Jian, Zhang, Shangming
Formato: research tables/charts Journal Article
Publicado: Sage Publications Inc. Feb2026
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=190799068&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 190799068
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00185787
        1WYH
      jtl: Hospital Pharmacy
      issn: 00185787
      maglogo: Y
    pubinfo:
      dt: Feb2026
      vid: 61
      iid: 1
      pid: 344
      pub: Sage Publications Inc.
      place: Thousand Oaks, California
    artinfo:
      ui:
        190799068
        188693623
        190799068
        190799068
        10.1177/00185787251348650
        190799068
      ppf: 59
      ppct: 9
      formats:
      tig:
        atl: Association Between Irbesartan and Erectile Dysfunction: A Comprehensive Analysis Incorporating Real-World Pharmacovigilance and Mendelian Randomization.
      aug:
        au:
          Chen, Kaiqin
          Cheng, Rui
          Guo, Jian
          Zhang, Shangming
        affil: Xiang'an Hospital of Xiamen University, Xia Men, Fu Jian, China
      sug:
        subj:
          Mendelian Randomization
          Pharmacovigilance
          Erectile Dysfunction Chemically Induced
          Irbesartan Adverse Effects
          Irbesartan Pharmacodynamics
          Erectile Dysfunction Risk Factors
          Adverse Drug Event
          Databases, Health Evaluation
          Risk Assessment
          Human
          Male
          Adolescence
          Adult
          Middle Age
          Aged
          Hypertension Drug Therapy
          Odds Ratio
          Probability
          Neural Networks (Computer)
          Confidence Intervals
          Genetic Screening
          UK Biobank
          Descriptive Statistics
          Data Analysis Software
          Irbesartan Administration and Dosage
          Nervous System Diseases Chemically Induced
          Gastrointestinal Diseases Chemically Induced
          Metabolic Diseases Chemically Induced
          Genital Diseases, Male Chemically Induced
          Chi Square Test
          Data Analysis, Statistical
          Age Factors
          Funding Source
          Adolescent: 13-18 years
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Aged: 65+ years
          Male
      ab: Background: Irbesartan is widely used for hypertension management, but its relationship with erectile dysfunction (ED) is unclear. This study combines real-world data from the FAERS database with Mendelian randomization to explore this potential association. Methods: We conducted multiple pharmacovigilance analyses, including odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Gamma-Poisson Shrinker (GPS), to assess the association between irbesartan and ED. Additionally, Mendelian randomization was applied to investigate the causal relationship. Results: The pharmacovigilance analyses indicated a significant association between irbesartan and ED: ROR = 3.38 (95% CI: 2.36-4.84), PRR = 3.38 (95% CI: 2.36-4.83), IC = 1.75 (95% CI: 1.13-2.17), and EBGM = 3.37 (95% CI: 2.36-4.83). Mendelian randomization analysis also showed a significant correlation using the inverse variance weighting method (P =.01, β = 10.06, SE = 3.91), with other methods yielding consistent directional results. Conclusion: Our study reveals a significant association and potential causal link between irbesartan use and ED. These findings highlight the need to consider ED as a possible adverse effect when prescribing irbesartan. Further research and clinical monitoring are essential to understand the underlying mechanisms and develop strategies to mitigate this side effect.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N